Phase I/II Trial to Establish the Safety and Preliminary Efficacy of the Combination of Docetaxel, Prednisone, and SOM 230 (Pasireotide) in Metastatic Castrate Resistant Prostate Cancer (CRPC).
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 08 Dec 2016
At a glance
- Drugs Pasireotide (Primary) ; Docetaxel; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 02 Dec 2016 Planned End Date changed from 1 Aug 2016 to 1 Mar 2017.
- 02 Dec 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Mar 2017.